胰高血糖素样肽-1类似物新药的研发进展

[1] Compounds,methodsand formulations for the oral delivery of a glucagons-like peptide (GLP)-1 compound or a melanocortin-4 receptor (MC4)agonistpeptide. Jason HR,Nickolaus JL,McNeill J,et al. US7662771B2 . 2010

[2] Effectsof once-weeklydosing of a long-acting release formulation of exenatide on glu-cose control and body weight in subjects with type 2 diabetes. Kim D,MacConell L,Zhuang D,et al. Diabetes Care . 2007

[3] A model for receptor-peptide binding at the glucagon-like peptide-1 (GLP-1) receptor through the analysis of truncated ligands and receptors. Al-Sabah S,Donnelly D. British Journal of Pharmacology . 2003

[4] Treatment with the human once-weekly glucagon-like peptide-1 analog taspoglutide in combination with metformin improves glycemic control and lowers body weight in patients with type 2 diabetes inadequately controlled with metformin alone: a double-blind p. Nauck MA,Ratner RE,Kapitza C,et al. Diabetes Care . 2009

[5] Glucagon-like peptide1receptor agonist ZP10A increases insulin mRNA expression and prevents diabetic progression in db/db Mice. Thorkildsen C,Neve S,Larsen BD,et al. Journal of Pharmacology and Experimental Therapeutics . 2003

[6] Evaluation of therapeutic potentials of site-specific PEGylated glucagon-like peptide-1isomers as a type2anti-diabetic treatment:Insulinotropic activity,glucose-sta-bilizing capability,and proteolytic stability. Youn YS,Chae SY,Lee S,et al. Biochemical Pharmacology . 2007

[7] Treatment With the Human Once-Weekly Glucagon-Like Peptide-1 Analog Taspoglutide in Combination With Metformin Improves Glycemic Control and Lowers Body Weight in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Alone: A double-blind placebo-controlled study[J] . Nauck, Michael A,Ratner, Robert E,Kapitza, Christoph,Berria, Rachele,Boldrin, Mark,Balena, Raffaella. &nbspDiabetes Care . 2009 (7)

[8] An albumin-exendin-4 conjugate engages central and peripheral circuits regulating murine energy and glucose Homeostasis [J]. GASTROENTEROLOGY, 2008, 134 (04) : 1137 - 1147

[9] A recombinant human glucagon-like peptide(GLP)-1-albumin protein(albugon)mimics peptidergic activation of GLP-1receptor-dependent pathways coupled with satiety,gastrointestinal motility,and glucose homeostasis. Baggio LL,Huang Q,Brown TJ,et al. Diabetes . 2004

[10] Pharmacokinetics and tolerability of a novel long-acting glucagon-like peptide-1 analog, CJC-1131, in healthy and diabetic subjects. Tiessen RG,Castaigne JP,Dreyfus JF,Nemansky M,Kruizinga HH,van Vliet AA. International Journal of Clinical Pharmacology Research . 2008

[1] Compounds,methodsand formulations for the oral delivery of a glucagons-like peptide (GLP)-1 compound or a melanocortin-4 receptor (MC4)agonistpeptide. Jason HR,Nickolaus JL,McNeill J,et al. US7662771B2 . 2010

[2] Effectsof once-weeklydosing of a long-acting release formulation of exenatide on glu-cose control and body weight in subjects with type 2 diabetes. Kim D,MacConell L,Zhuang D,et al. Diabetes Care . 2007

[3] A model for receptor-peptide binding at the glucagon-like peptide-1 (GLP-1) receptor through the analysis of truncated ligands and receptors. Al-Sabah S,Donnelly D. British Journal of Pharmacology . 2003

[4] Treatment with the human once-weekly glucagon-like peptide-1 analog taspoglutide in combination with metformin improves glycemic control and lowers body weight in patients with type 2 diabetes inadequately controlled with metformin alone: a double-blind p. Nauck MA,Ratner RE,Kapitza C,et al. Diabetes Care . 2009

[5] Glucagon-like peptide1receptor agonist ZP10A increases insulin mRNA expression and prevents diabetic progression in db/db Mice. Thorkildsen C,Neve S,Larsen BD,et al. Journal of Pharmacology and Experimental Therapeutics . 2003

[6] Evaluation of therapeutic potentials of site-specific PEGylated glucagon-like peptide-1isomers as a type2anti-diabetic treatment:Insulinotropic activity,glucose-sta-bilizing capability,and proteolytic stability. Youn YS,Chae SY,Lee S,et al. Biochemical Pharmacology . 2007

[7] Treatment With the Human Once-Weekly Glucagon-Like Peptide-1 Analog Taspoglutide in Combination With Metformin Improves Glycemic Control and Lowers Body Weight in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Alone: A double-blind placebo-controlled study[J] . Nauck, Michael A,Ratner, Robert E,Kapitza, Christoph,Berria, Rachele,Boldrin, Mark,Balena, Raffaella. &nbspDiabetes Care . 2009 (7)

[8] An albumin-exendin-4 conjugate engages central and peripheral circuits regulating murine energy and glucose Homeostasis [J]. GASTROENTEROLOGY, 2008, 134 (04) : 1137 - 1147

[9] A recombinant human glucagon-like peptide(GLP)-1-albumin protein(albugon)mimics peptidergic activation of GLP-1receptor-dependent pathways coupled with satiety,gastrointestinal motility,and glucose homeostasis. Baggio LL,Huang Q,Brown TJ,et al. Diabetes . 2004

[10] Pharmacokinetics and tolerability of a novel long-acting glucagon-like peptide-1 analog, CJC-1131, in healthy and diabetic subjects. Tiessen RG,Castaigne JP,Dreyfus JF,Nemansky M,Kruizinga HH,van Vliet AA. International Journal of Clinical Pharmacology Research . 2008